385 results match your criteria: "University hospital of Lyon[Affiliation]"
J Cancer Surviv
August 2024
UR 3279, CERESS - Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France.
Purpose: In the context of pediatric cancer, siblings' adaptation and needs have been previously investigated; however, research on the long-term consequences on siblings, especially on their family environment, is scarce. We aimed to (1) assess the family functioning (FF) perceived by siblings of childhood leukemia survivors long after diagnosis and (2) explore characteristics likely associated and investigate associations with psycho-behavioral and social factors.
Methods: Childhood leukemia survivors' siblings older than 11 years were recruited through the LEA cohort, a French long-term follow-up program, and completed the family assessment device (FAD).
Biol Rev Camb Philos Soc
October 2023
CNRS UMR8590, Institut d'Histoire et Philosophie des Sciences et des Technique, University Paris I Panthéon-Sorbonne, 13 rue du Four, Paris, 75006, France.
Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer.
View Article and Find Full Text PDFAnn Neurol
August 2023
Department of Neuroscience, University of Naples "Federico II", Naples, Italy.
Sleep
June 2023
Analytical Neurophysiology Lab, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.
Circ Genom Precis Med
June 2023
Laboratoire de Cardiogénétique Moléculaire (A.J., G.M.), Hospices Civils de Lyon, Lyon, France.
Parasite
April 2023
Parasitology-Mycology Laboratory, French National Reference Center for Echinococcosis, University Hospital of Besançon and Franche-Comté University, F-25030, Besançon, France - UMR 6249 CNRS-Franche-Comté University « Chrono-Environnement », F-25030, Besançon, France - Visceral Surgery/Liver Transplant Unit, French National Reference Center for Echinococcosis, University Hospital of Besançon and Franche-Comté University, F-25030, Besançon, France.
Alveolar echinococcosis (AE) is a severe parasitic infection caused by the ingestion of Echinococcus multilocularis eggs. While higher incidence and faster evolution have been reported in immunosuppressed patients, no studies have been performed specifically on AE in transplant patients. We searched for all de novo AE cases diagnosed between January 2008 and August 2018 in solid organ transplant (SOT) recipients included in the Swiss Transplant Cohort Study and the FrancEchino Registry.
View Article and Find Full Text PDFBrain Sci
March 2023
Skull Base and Pituitary Unit, Department of Neurosurgery B, Neurological Hospital Pierre Wertheimer, Bron, 69677 Lyon, France.
Craniopharyngiomas are commonly classified as low-grade tumors, although they may harbor a malignant behavior due to their high rate of recurrence and long-term morbidity. Craniopharyngiomas are classically distinguished into two histological types (adamantinomatous and papillary), which have been recently considered by the WHO classification of CNS tumors as two independent entities, due to different epidemiological, radiological, histopathological, and genetic patterns. With regard to papillary craniopharyngioma, a BRAF V600 mutation is detected in 95% of cases.
View Article and Find Full Text PDFJ Clin Invest
June 2023
Laboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Br J Haematol
June 2023
Department of Pediatric Hematology Oncology, University Hospital of Nancy, Nancy, France.
Haematopoietic stem cell reinjection may be a curative option for poor graft function after haematopoietic stem cell transplantation; however, literature supporting its use remains limited. We conducted a multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, including 55 patients. We demonstrated response rates of nearly 40% and two-year survival of more than 60% in the context of an otherwise deadly complication and we observed that the timing of injection and the degree of cytopenia are strongly associated with outcomes.
View Article and Find Full Text PDFOphthalmol Ther
June 2023
Allergan, an AbbVie Company, Courbevoie, France.
Introduction: To evaluate real-world efficacy, safety, and treatment patterns with the dexamethasone intravitreal implant (DEX) in diabetic macular edema (DME) in France.
Methods: In this prospective, multicenter, observational, noncomparative, post-reimbursement study, consecutively enrolled patients with DME had a baseline evaluation on day 0. Those treated with DEX on day 0 were to be reevaluated at week 6 and months 6, 12, 18, and 24.
J Visc Surg
April 2023
Department of digestive surgery, center of bariatric surgery, university hospital of Édouard-Herriot, hospices civils de Lyon, Lyon, France; Specialized center of obesity, university hospital of Lyon, hospices civils de Lyon, Pierre-Bénite, France; University Claude Bernard Lyon 1, Lyon, France; Carmen lab, Inserm unit 1060, France.
The outcomes of bariatric surgery, while often impressive, are not universally satisfactory; they vary from patient to patient and from operation to operation. Between 20-30% of patients experience suboptimal weight loss or substantial weight regain early in their postoperative course. Confronted with this chronic disease, and given that failures are difficult to manage, it is essential to better characterize obesity preoperatively, considering other metrics beyond just the body mass index (BMI), to select the best candidates for surgery and optimize the benefit/risk ratio.
View Article and Find Full Text PDFPatient Educ Couns
June 2023
Lyon Institute for Aging, Hospices Civils de Lyon, F-69000 Lyon, France; Clinical Research Centre (CRC) - VCF (Aging - Brain - Frailty), Charpennes Hospital, University Hospital of Lyon, Villeurbanne, F-69000 Lyon, France; Neuroscience Research Centre of Lyon (CRNL), F-69000 Lyon, France.
Objectives: To formalize a proposal for educational approach for patients with Alzheimer's disease and related dementias (ADRD) and caregivers across existing diagnosis/care organizations and structures.
Methods: Three steps:1/ identifying the existing organizations and structures that could be involved in educational care; 2/ identifying the main educational skills of interest for ADRD patients and caregivers; 3/ conducting a survey among these organizations and structures to achieve a mapping proposal of educational care.
Results: Nine organizations and structures, and 29 educational skills of interest were identified for the step 3 survey.
Res Pract Thromb Haemost
February 2023
Laboratory of Hematology, University Hospital, Bordeaux, France.
Background: and mutations are the most frequent molecular causes of -negative myeloproliferative neoplasms (MPN). Patients with mutations are at lower risk of thrombosis than patients with . We hypothesized that -mutated blood platelets would have platelet function defects that might explain why these patients are at lower risk of thrombosis.
View Article and Find Full Text PDFNephrol Ther
April 2023
Charpennes Hospital, Pharmaceutical Unit, University Hospital of Lyon, 69100 Villeurbanne, France.
Objective: Regarding older patients, multiple chronic conditions lead to the intake of multiple medications, involving a higher risk of adverse drug events. In older patients with advanced chronic kidney disease, the medication exposure was poorly explored. The aim of this study was to describe the use of potentially inappropriate medications and medications with anticholinergic and sedative properties in older community-dwelling patients with advanced chronic kidney disease.
View Article and Find Full Text PDFFront Neurol
February 2023
Neurology Department, Toulouse University Hospital, Toulouse, France.
While new-onset status epilepticus (NOSE) is a harbinger of chronic epilepsy, prospective medical data are sparse in terms of specifying whether the evolution of status epilepticus (SE) and seizure expression in NOSE resembles what occurs in patients who have already been diagnosed with epilepsy [non-inaugural SE (NISE)] in all aspects apart from its inaugural nature. The aim of this study was to compare the clinical, MRI, and EEG features that could distinguish NOSE from NISE. We conducted a prospective monocentric study in which all patients ≥18 years admitted for SE over a 6-month period were included.
View Article and Find Full Text PDFTransplant Cell Ther
June 2023
Department of Pediatric Hematology, Immunology and Oncology, APHM, La Timone Children's Hospital, Marseille, France; CEReS Research Unit EA 3279 and Department of Public Health, Hôpital de la Timone, Marseille, France.
Ovarian function impairment and infertility are among the most frequent late effects after hematopoietic stem cell transplantation (HSCT). The aim of this study was to evaluate ovarian function, occurrence of premature ovarian insufficiency (POI), and spontaneous pregnancy in a large cohort of adult survivor women who had undergone HSCT for leukemia before puberty. We conducted a retrospective observational study in women from the national cohort L.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
Biochemistry and Toxicology Laboratory, Lyon Sud Hospital, University Hospital of Lyon, CEDEX, 69495 Pierre-Bénite, France.
Performances of metabolomic methods have been widely studied on biological matrices such as serum, plasma, and urine; but much less on in vitro cell extracts. While the impact of cell culture and sample preparation on results are well-described, the specific effect of the in vitro cellular matrix on the analytical performance remains uncertain. The aim of the present work was to study the impact of this matrix on the analytical performance of an LC-HRMS metabolomic method.
View Article and Find Full Text PDFCancer Treat Res Commun
May 2023
Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69373, Lyon Cedex, France. Electronic address:
Purpose: The objective of this study was to describe filgrastim biosimilar-Sandoz modalities of use in patients receiving cytotoxic chemotherapy regimens with a rest period of ≤14 days and to investigate the incidence of febrile neutropenia (FN) in routine clinical practice.
Methods: This was a French, multicenter, prospective and descriptive, non-interventional study including patients with breast, lung, gastrointestinal cancer or a lymphoma initiating filgrastim biosimilar-Sandoz treatment and in the context of cytotoxic chemotherapy with a rest period not exceeding 14 days. Data were collected during two routine clinical visits on the modalities of use of filgrastim biosimilar-Sandoz, on the incidence of neutropenia events and on adverse events.
Eur J Haematol
June 2023
Haemophilia Treatment Centre, University Hospital of Lyon and French Reference Centre on Haemophilia, Lyon, France.
Introduction: The rare coagulation disorders may present significant difficulties in diagnosis and management. In addition, considerable inter-individual variation in bleeding phenotype is observed amongst affected individuals, making the bleeding risk difficult to assess in affected individuals. The last international recommendations on rare inherited bleeding disorders (RIBDs) were published by the United Kingdom Haemophilia Centre Doctors' Organisation in 2014.
View Article and Find Full Text PDFHistopathology
May 2023
CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.
Aims: Recently, YAP1 fusion genes have been demonstrated in eccrine poroma and porocarcinoma, and the diagnostic use of YAP1 immunohistochemistry has been highlighted in this setting. In other organs, loss of YAP1 expression can reflect YAP1 rearrangement or transcriptional repression, notably through RB1 inactivation. In this context, our objective was to re-evaluate the performance of YAP1 immunohistochemistry for the diagnosis of poroma and porocarcinoma.
View Article and Find Full Text PDFFertil Steril
April 2023
CEReS Research Unit EA 3279 and Department of Public Health, Hôpital de la Timone, Marseille, France; Department of Pediatric Hematology, Immunology and Oncology, AP-HM, La Timone Children's Hospital, Marseille, France.
J Invest Dermatol
May 2023
Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
Liver Int
March 2023
Liver Unit, Avicenne Hospital, AP-HP, Bobigny, France.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, with up to 90% of HCC cases occurring in the setting of underlying cirrhosis. Therapeutic landscape for advanced HCC has dramatically changed in recent years with the advent of immunotherapy, including several combinations. Data suggest that the surrounding liver milieu may influence tumour response.
View Article and Find Full Text PDFViruses
November 2022
Department of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Avenue Albert Raimond, CEDEX 02, 42055 Saint-Etienne, France.
Within the successive waves that occurred during the SARS-CoV-2 pandemic, recommendations arose to test symptomatic and contact subjects by using rapid antigen devices directed against the viral nucleocapsid protein with the aim to isolate contagious patients without delay. The objective of this study was to evaluate the ability of four rapid lateral-flow tests (RLFT) that were commercially available on the French market in 2022 to recognize various strains of SARS-CoV-2. Series of five-fold dilutions of seven viral suspensions belonging to different lineages of SARS-CoV-2 (19A, 20A, Alpha, Beta, Gamma, Delta and Omicron) were used to evaluate the analytical sensitivity of four commercially available RLFTs (manufacturers: Abbott, AAZ, Becton-Dickinson and Biospeedia).
View Article and Find Full Text PDFEpilepsy Res
January 2023
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, 12 Queen Square, London, WC1N 1PJ, United Kingdom.
Collaboration is essential to the conduct of basic, applied and clinical research and its translation into the technologies and treatments urgently needed to improve the lives of people living with brain diseases and the health professionals who care for them. EPICLUSTER was formed in 2019 by the European Brain Research Area (EBRA) to support the coordination of epilepsy research in Europe. A key objective was to provide a platform to discuss shared research priorities by bringing together scientists and clinicians with multiple stakeholders including patient organisations and industry and the networks and infrastructures that provide healthcare and support research.
View Article and Find Full Text PDF